Hikma Pharmaceuticals USA Inc. v. Vanda Pharmaceuticals Inc.

Pending petition
Docket No. Op. Below Argument Opinion Vote Author Term
18-817 Fed. Cir. TBD TBD TBD TBD TBD

Issue: Whether patents that claim a method of medically treating a patient automatically satisfy Section 101 of the Patent Act, even if they apply a natural law using only routine and conventional steps.

SCOTUSblog Coverage

DateProceedings and Orders (key to color coding)
Oct 26 2018Application (18A461) to extend the time to file a petition for a writ of certiorari from November 12, 2018 to December 27, 2018, submitted to The Chief Justice.
Oct 31 2018Application (18A461) granted by The Chief Justice extending the time to file until December 27, 2018.
Dec 27 2018Petition for a writ of certiorari filed. (Response due January 28, 2019)
Jan 22 2019Motion to extend the time to file a response from January 28, 2019 to February 12, 2019, submitted to The Clerk.
Jan 23 2019Motion to extend the time to file a response is granted and the time is extended to and including February 12, 2019.
Jan 28 2019Brief amici curiae of Intellectual Property and Innovation Professors, Engine Advocacy, et al. filed.
Jan 28 2019Brief amici curiae of The Association for Accessible Medicines and Certain Individual Companies filed.
Feb 12 2019Brief of respondent Vanda Pharmaceuticals USA, Inc. in opposition filed.
Feb 26 2019Reply of petitioners Hikma Pharmaceuticals USA Inc., et al. filed.
Feb 27 2019DISTRIBUTED for Conference of 3/15/2019.
Mar 15 2019Letter of Hikma Pharmaceuticals USA Inc., et al. received.
Mar 18 2019The Solicitor General is invited to file a brief in this case expressing the views of the United States.
 
Share:
Term Snapshot
Awards